AbbVie has announced sustained virological response rates of up to 99% associated with its investigational all-oral, interferon-free therapy for patients with genotype 1 hepatitis C.
The company released results of four additional studies that assessed its regimen of investigational agents, including ABT-450 with ritonavir, ABT-267 and ABT-333, with and without ribavirin, according to a press release. AbbVie completed six phase 3 studies assessing the combination therapy among a varying group of patients.
In the PEARL-II study, treatment-experienced patients with genotype 1b HCV demonstrated a sustained virological response (SVR) of 97% when receiving the regimen with ribavirin and 100% without ribavirin. In the PEARL-III study, treatment-naive patients had an SVR of 99% with the regimen, both with and without ribavirin. In the PEARL-IV study, treatment-naive patients with genotype 1a HCV who received the regimen had an SVR of 97% with ribavirin and 90% without ribavirin.
In the TURQUOISE-II study, patients with genotype 1 HCV with compensated cirrhosis experienced an SVR of 92% when they received the regimen with ribavirin for 12 weeks and 96% when they received it for 24 weeks. In the SAPPHIRE-1 study, treatment-naive patients with genotype 1 HCV received the regimen with ribavirin and had an SVR of 96%. A similar study with treatment-experienced patients, SAPPHIRE-2, also demonstrated an SVR rate of 96%.
The fixed-dose combination regimen includes 150 mg ABT-450 with 100 mg ritonavir, co-formulated with 25 mg ABT-267, and 250 mg ABT-333.